VIETNAM PHARMACEUTICAL INDUSTRY
Vietnam Pharmaceutical industry uses about 60,000 tons of pharmaceutical materials and 80-90% of them are imported. In particular, China and India have been the two countries with the largest export turnover of pharmaceutical materials in Vietnam for many years.
The total value of the pharmaceutical industry in 2018 was estimated at 5.9 million USD, of which imported pharmaceuticals made a significant contribution to the growth rate. Vietnam pharmaceutical import turnover reached USD 2,795.9 million, almost equal to the same period last year. Pharmaceutical exports in Vietnam have continuously increased since 2012, in 2018, pharmaceutical exports reached approximately 5.6% of the total import value, but mainly exported on the spot.
According to information on drug prices declared on the website of the Drug Administration of the Ministry of Health, from the beginning of the year to 30th November , 2018: About imported drugs, there are 482 turns of prescription drugs price declaration, 26 times of goods re-declared prices; About domestic drugs, there are 957 items of price declaration, 152 items of goods are re-declared. Thus, the total amount of drug re-declared accounted for less than 0.5% of the total drug circulation volume.
Pharmaceutical is an essential demand group, so economic growth has almost no effect on the growth rate of the industry. With WTO, Vietnam’s pharmaceutical market has gradually opened its doors. After the CPTPP Agreement signed on March 8, 2018, domestic Pharmaceutical Companies will be put under greater competitive pressure from foreign companies.
M & A trends between domestic and foreign businesses took place strongly for drug production in franchise and distribution sectors. Vietnam’s pharmaceutical industry is forecasted to continue double-digit growth compared to the current value growth but tend to decrease compared to the 2010-2015 period. Most businesses in the pharmaceutical industry still maintain a positive business situation with positive gross profit and net profit in the period of 2016 – 2017.
Abbreviations
Report summary
1. Business environment
1.1. Macroeconomic situation
1.2. Legal framework
2. Pharmaceutical Industry Overview
2.1. Global Pharmaceutical Industry 
2.1.1. Production – Consumption
2.2. Vietnam Pharmaceutical Industry Overview
2.2.1. History of Vietnam Pharmaceutical Industry
2.2.2. Industry Position
2.2.3. Industry Scale and Feature
2.2.4. Value Chain of Vietnam Pharmaceutical Industry
2.2.5. Production
2.2.6. Consumption
2.2.7. Export – Import
2.2.8. Price movement
2.3. Industry planning
2.4. Driving forces of industry development
3. Enterprise analysis
3.1. Profitability Ratios
3.2. Cost structure
3.3. Asset Management Ratios
3.4. Capital Structure
3.5. Solvency
3.6. Return on Investment
DHG Pharmaceutical Joint Stock Company
TRAPHACO Joint Stock Company
Domesco Medical Import Export JSC
Imexpharm Pharmaceutical JSC
OPC Pharmaceutical JSC
S.P.M JSC
Vimedimex Medi – Pharma JSC
Ha Tay Pharmaceutical JSC
Ben Tre Pharmaceutical JSC
Lam Dong Pharmaceutical JSC
List of tables
Table 1: Medicine production by type, 2013 – 3M/2018e
Table 2: Vietnam’s top import partners, 3M/2018
Table 3: Top exporting enterprises, 3M/2018
Table 4: Price movements of some major drugs in the market, 12/2016 – 3/2018
Table 5: The difference in the price of some drugs at some drug stores, 2017
Table 6: 10 typical pharmaceutical enterprises in 2017 
List of figures
Figure 1: GDP growth, 2011 – 3M/2018
Figure 2: Consumer Price Index for Medicines and Health Services, 2012 – 3M/2018
Figure 3: VND/USD exchange rate, 3/2016 – 3/2018
Figure 4: VND/CNY exchange rate, 2016 – 3/2018
Figure 5: Population and population growth, 2006 -2017
Figure 6: Population structure, 1999 – 2016
Figure 7: Global spending on medicines, 2010 – 2016e
Figure 8: World sales of prescription drugs, 2010 – 2016
Figure 9: Consumption structure by types of medicines, 2011 – 2016
Figure 10: Consumption market share by group, 2016
Figure 11: World’s top 10 consumed phamaceuticals, 2016
Figure 12: Classification of medicine markets by distribution methods
Figure 13: Classification of medicine markets by ownership
Figure 14: Domestic pharmaceutical production value, 2010 – 2017e
Figure 15: Pharmaceutical market value, 2010 – 2017e
Figure 16: Value ratio of domestically produced medicines in Vietnam, 2010 – 2017e
Figure 17: Domestically produced medicine consumption, 2010 – 2017e
Figure 18: Spending on medicines in Vietnam, 2009 – 2017e
Figure 19: Spending on medicines per capita in some countries, 2016e
Figure 20: Medicines consumption structure by channel, 2010 – 2017e
Figure 21: Market value of prescription  drugs (ETC), 2011 – 2017e
Figure 22: Market value of non-presciption drugs (OTC), 2010 – 2017e
Figure 23: Patened drugs (Patent), 2010 – 2017e
Figure 24: Generic drug market, 2010 – 2017e
Figure 25: Pharmaceutical imports, 2012 – 3M/2018e
Figure 26: Pharmaceutical imports, 3M/2017 – 3M/2018e
Figure 27: Pharmaceutical exports, 2012 – 3M/2018
Figure 28: Export structure by country, 3M/2018
Figure 29: Rate of drug re-price (increase), 2013 – 2016
Figure 30: Total healthcare expenses, 2010 – 2016f
Figure 31: Population tower, 2016
Figure 32: Over-60 population growth in the world, 1950 – 2050
Figure 33: Profitability, 2016 – 2017
Figure 34: COGS/NR, 2016 – 2017
Figure 35: Selling expenses, 2016 – 2017
Figure 36: Administrative expenses, 2016 – 2017
Figure 37: Days in inventory, 2016 – 2017
Figure 38: Days of sales outstanding, 2016 -2017
Figure 39: Asset turnover
Figure 40: Self-financing ratio, 2016 – 2017
Figure 41: Solvency, 2016 – 2017
Figure 42: Profit ratio, 2016 – 2017